Imugene | Cancer Immunotherapies

A clinical stage immuno-oncology #biotech developing a range of new treatments seeking to activate the immune system of cancer patients. #Immunotherapy $IMU

[Imugene | Cancer Immunotherapies @TeamImugene]

Turning a scientific idea into a therapy takes time.

Years of testing. Validation. Refinement.

Our latest data, alongside @10NewsAU coverage, shows the progress we are making step by step.

https://t.co/NBksIxRfs5

#Imugene #Biotech #ClinicalTrials $IMU

[Imugene | Cancer Immunotherapies @TeamImugene]

“We know this is working in a late-stage patient population… with complete clearance of cancer in some patients.”

Encouraging signals continue from our azer-cel program, even in heavily pre-treated cases.

Our CEO Leslie Chong on Fear & Greed discussing the path forward.

Watch:
https://t.co/kasgKUHI78

$IMU #CancerResearch #Immunotherapy #CellTherapy #CART #Biotech #ClinicalTrials #Oncology #DrugDevelopment

[Imugene | Cancer Immunotherapies @TeamImugene]

Progress in biotech is built on collaboration between researchers, clinicians and industry.

No one works in isolation.

#Collaboration #Biotech #Research

[Imugene | Cancer Immunotherapies @TeamImugene]

Our CEO Leslie Chong speaking at the Bell Potter Healthcare Horizons Summit, alongside 15+ biotech companies presenting across the program.

A great opportunity to share updates on our progress as we continue to advance our clinical pipeline and immunotherapy technologies.

#Biotech #Healthcare #Immunotherapy

[Imugene | Cancer Immunotherapies @TeamImugene]

New Phase 1b Azer-cel trial data reports responses in additional blood cancers

Results from the CAR-T naïve cohort show:

• 100% ORR — CLL/SLL
• 80% ORR — marginal zone lymphoma

$IMU ASX announcement: https://t.co/PYFU0XMi0g

#Imugene #BloodCancer #ClinicalTrials

[Imugene | Cancer Immunotherapies @TeamImugene]

Thank you to @10NewsAU and @EmmaOlsenNZ for sharing this powerful patient story highlighting azer-cel, Imugene’s allogeneic CAR-T therapy.

“It’s given me another chance at life.”

Stories like these remind us why this work matters.

https://t.co/SmHqUf2187

#Biotechnology #Immunotherapy #CARTCellTherapy #CancerResearch

[Imugene | Cancer Immunotherapies @TeamImugene]

This International Women’s Day we recognise the women across science, clinical research and operations who contribute to advancing medical research every day.
#InternationalWomensDay #WomenInScience

[Imugene | Cancer Immunotherapies @TeamImugene]

A powerful story of a clinical trial participant given another chance at life thanks to azer-cel, Imugene’s investigational allogeneic CAR-T therapy, will air on @10NewsFirst tonight at 6pm. Report by @EmmaOlsenTV.
$IMU

[Imugene | Cancer Immunotherapies @TeamImugene]

Clinical trials are carefully designed, independently monitored, and essential to improving future treatments.

#ClinicalTrials #MedicalResearch #Healthcare

[Imugene | Cancer Immunotherapies @TeamImugene]

A powerful story of a clinical trial participant given another chance at life thanks to azer-cel, Imugene’s investigational allogeneic CAR-T therapy, will air on @10NewsAU around Australia this weekend.
Report by Emma Olsen

#Imugene #10NewsFirst #AzerCel

[Imugene | Cancer Immunotherapies @TeamImugene]

Drug development is a team effort.

Scientists, clinicians, trial coordinators and patients all play a role in moving research forward.

#BiotechCareers #Science #STEM

[Imugene | Cancer Immunotherapies @TeamImugene]

Immuno-oncology in simple terms: helping the immune system recognise and respond to cancer.

That’s the focus of our work at Imugene.

#ImmunoOncology #CancerResearch #Biotech

[Imugene | Cancer Immunotherapies @TeamImugene]

Our first patient remains cancer free, more than 22+ months on.

While individual outcomes don’t predict broader results, moments like this reinforce why the work matters. As outlined in our half-year results, we continue to progress our clinical programs with a disciplined, step-by-step approach.

#PatientImpact #ClinicalResearch #Biotech #ImmunoOncology

[Imugene | Cancer Immunotherapies @TeamImugene]

Today, Leslie Chong joined the Fear & Greed Podcast @PodcastFear to talk about the realities of running a biotech company and progressing life-changing therapies.

“We know this is working in a late-stage patient population, with some patients seeing a complete clearance of their cancer.”

Listen: https://t.co/RoZSpdnXzi

#biotech #immunooncology #cancerresearch #ASX #healthcare

[Imugene | Cancer Immunotherapies @TeamImugene]

Good results start with good trial design.

Clear endpoints and disciplined methodology are essential for generating credible clinical data.

#ClinicalTrials #Biotech #ClinicalResearch

[Imugene | Cancer Immunotherapies @TeamImugene]

Progress in biotech isn’t about speed.
It’s about evidence, discipline and clarity.

#Biotech #LifeSciences #ClinicalResearch

[Imugene | Cancer Immunotherapies @TeamImugene]

Clinical progress matters because patients matter.

Azer-cel has shown an 82% response rate in trials, including a patient cancer-free after 21+ months.

#CancerResearch #ClinicalData #IMU

[Imugene | Cancer Immunotherapies @TeamImugene]

For many blood cancer patients, waiting weeks for treatment isn’t an option.

Imugene’s azer-cel is an off-the-shelf CAR-T therapy designed to be delivered in days, not weeks, and is already showing strong responses in heavily pre-treated patients.

Faster access could change everything.

More in Biotech Daily: https://t.co/juDSZ1F9gD

#Hematology #CellTherapy #CARTcelltherapy #BiotechNews #Immunotherapy

[Imugene | Cancer Immunotherapies @TeamImugene]

Yesterday marked International Day of Women and Girls in Science, a moment to recognise the critical role women play in driving progress across research, innovation and leadership.

We’re proud to support and celebrate the women shaping the future of science and setting the standard for the next generation.

#WomenInScience #STEM #Biotechnology